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Splenectomy is a powerful therapeutic procedure in a wide variety of medical disorders provided that it
is not undertaken lightly and the risks are weighed against the potential beneﬁts in each individual case.
Most of this risk seems to be due to the underlying splenectomy indication and not to splenectomy alone.
There has been an increased tendency in recent years towards splenic preservation to prevent not only
the risk of subsequent overwhelming post-splenectomy infection (OPSI) but the long term risk of car-
diovascular complications. As there is no condition that can be cured by splenectomy, this paper
reviewed the rationale behind the indications for, and the associated risks.
Method: Electronic searches of the medline (PubMed) database, Cochrane library, and science citation
index were performed to identify original published studies on splenectomy. Relevant articles were
searched from relevant chapters in specialized texts and all included.
 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Since the ﬁrst deliberate removal of a diseased spleen by Quit-
tenbaum in 1826 splenectomy has become a well established sur-
gical procedure.1 A spleenless existence was considered to be quite
safe as the spleen was considered unnecessary for life until 1952
when King and Schumacher drew attention to the risk of over-
whelming post splenectomy infection (OPSI).2 Since that time
enthusiasm for splenectomy has diminished. The spleen clearly
serves extremely important haematological and immunological
functions. As part of the reticulo-endothelial system and by
receiving 25% of the cardiac output, it plays a major part in the im-
mediate immunological response to blood-borne antigens akin to
the phagocytic role of ‘Kupffer’ cells of the liver in the portal circu-
lation.3 As the spleen is responsible for making antibodies and
removing bacteria, aged, antibody-coated and damaged blood cells,
thosewithout a spleenhavean impaired immune system.4,5 Because
of this, splenectomized patients have a more difﬁcult time recov-
ering from pneumonia, meningitis, haemophilus inﬂuenzae (Hib)
ﬂu, sepsis, nosocomial infections, babesiosis (a tick-borne disease),
malaria and other parasitic diseases and gram-negative bacterial
diseases from animal bites.6e8 Although the liver can perform this
function in the absence of the spleen, higher levels of speciﬁc anti-
body and an intact complement system are probably required.5 Asciates Ltd. Published by Elsevier Ltthe spleen also destroys andmodiﬁes abnormal red cells, sequesters
30e40% of the circulating platelet pool and plays a role in the
regulation of plasma volume, the spleen is usually involved in hae-
matological disorders.9,10 Infact, the most frequent medical indica-
tion for splenectomy is a haematologic disorder.11 Overwhelming
bacterial sepsis as a complication in persons with asplenia, is now
infrequent because of pneumococcal vaccinations, prophylactic
penicillin, and promptmedical attention at theﬁrst sign of fever.12,13
However, during the past decade evidence has emerged that an
increased risk of thrombosis, both venous and arterial, may result
fromsplenectomy.14 The increased riskof venous thromboembolism
is particularlywithin the splenoportal system. This complicationhas
been described in diverse asplenic states including hereditary
spherocytosis (HS), thalassaemia, other haemolytic anaemias, and
trauma.14e16 In thalassaemiaand sickle cell disease, another vascular
complication, pulmonary hypertension (PH), has also been
described following splenectomy, with some studies reporting PH
prevalence as high as 75%.17,18
Splenectomy may have an impact on immunological function
but there is no increased cancer risk among patients splenectom-
ized because of trauma.1 A recent study revealed an increased risk
for some speciﬁc cancer sites in patients who underwent splenec-
tomy for non-traumatic reasons, although the effect of treatments
for the underlying disease and lifestyle habits such as cigarette
smoking could not be ruled out in explaining these excess risks.19
In most institutions, trauma is the primary indication for sple-
nectomy, although it is becoming less common in recent years with
more non-operative management of splenic injury.20d. All rights reserved.
Table 2
Grading of splenic injury e spleen injury SCALE (1994 Revision).24
Grade Injury type Description of injury
I Haematoma Subcapsular, <10%
Laceration Capsular tear, <1 cm parenchymal depth
II Haematoma Subcapsular, 10e15%, intra parenchymal, <5 cm d
Laceration Capsular tear, 1e3 cm parenchymal depth, trabecular
vessel not involved
III Haematoma Subcapsular, >50% or expanding, ruptured subcapsular or
parenchymal haematoma, intra parenchymal
haematoma >5 cm or expanding
Laceration >3 cm parenchymal depth or involving trabecular vessels
IV Laceration Involving segmental or hilar vessels producing major
devascularisation (>25%)
V Laceration Completely shattered spleen
Hilar vascular injury with devascularised spleen
❖ Advance one grade for multiple injuries up to Grade III.
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The normal spleen may serve as a major site of destruction of
abnormal cellular elements of the blood, e.g. in hereditary spher-
ocytosis, autoimmune anaemia, neutropenia and thrombocyto-
paenia. In the last two situations the spleen serves as the major site
of antibody production. The abnormal or diseased spleen gives rise
to two major syndromes; hypersplenism and symptomatic
splenomegaly. Hypersplenism refers to anaemia, neutropenia and/
or thrombocytopaenia arising singly or in combination as a direct
result of enlargement from whatever cause of the spleen. The
diagnosis is conﬁrmed retrospectively by correction of the cyto-
penia after splenectomy.1,9 Hypersplenic thrombocytopaenia re-
sults largely from increased platelet pooling within the spleen. As
many as 98% of total blood platelets may be sequestered in an
enlarged spleen and there is some evidence that splenomegaly
shortens platelet survival.10,11 The neutropenia of hypersplenism
probably results purely from an increased margination pool of
granulocytes in the vessels of the enlarged spleen. Hypersplenism
often also occurs in conditions that result in bone marrow failure.
Extramedullary haematopoiesis may occur in the inherited hae-
molytic anaemias which soon leads to hepatosplenomegaly and
bone expansion.9 Symptomatic splenomegaly is most commonly
encountered in lymphoproliferative and myeloproliferative disor-
ders. Increased metabolism may give rise to weight loss, fever,
hyperhidrosis, and vague left upper quadrant pain associated with
reduced blood ﬂow and resulting infarction.21
3. Indications for splenectomy
3.1. Absolute indications
The absolute indications include ruptured spleen, treatment of
splenic cysts and abscesses as all organ is usually affected, and
tumour resection involving adjacent organs (Table 1).1,9,22
It can be very difﬁcult to decide whether a patient needs an
emergency splenectomy after trauma, particularly when the pa-
tient is haemodynamically stable and has minimal signs of
abdominal injury. Special investigations do not provide absolute
answers and the risk of delayed and unnecessary laparotomies will
remain. Focused assessment with sonography for trauma (FAST) is
an excellent investigation for haemoperitoneum in blunt trauma
with a sensitivity of 88%.23 An emergency laparotomy is indicated
for a positive FAST in the shocked patient. A CT scan with intrave-
nous contrast is the single most useful investigation in the hae-
modynamically stable patient as it can assess for intraperitoneal
ﬂuid, solid organ injury and retroperitoneal haematoma. Repeated
scanning (ultrasound or CT) have been found particularly helpful in
assessing splenic bleeding or haematoma especially if patient is
slowly dropping her haemoglobin.24e26 Laparoscopy has no role in
trauma (Table 2).24Table 1
Absolute indications for splenectomy.
Splenic trauma
Splenic rupture
Spontaneous (tropical splenomegaly)
 Delayed rupture (subcapsular haematoma from trauma)
Splenic abscess (e.g. tuberculous infection)
Splenic cysts
Neoplasm
 As part of radical surgical oncological clearance of adjacent tumour. e.g.
locally advanced gastric carcinoma, pancreatic carcinoma
 Angioma
 Primary (rare)
Aneurysm of splenic arteryBecause the risks of uncontrolled haemorrhage and major
transfusion are greater thanOPSI, splenectomyshould beperformed
without delay if splenic bleeding is not controlled during laparot-
omy.However, if a splenic tear is foundwhich isnotactivelybleeding
with adherent clot it should be left undisturbed.22,24,25 The growing
awareness of possible long term complications and the increasing
reports of the failure of prophylactic measures have led increasingly
to the use of partial splenectomy with retention of some splenic
tissue wherever possible, especially in children following splenic
trauma.26,27 Splenic salvage techniques aremore feasible in children
because of the greater ratio of splenic capsular tissue to pulp tissue.
They include partial splenectomy, splenorrhaphy, ligation of
segmental vessels and capsular repair.1,28 Partial splenectomy may
be considered with deep tears to the hilum but should only be per-
formed if there are no other life-threatening injuries as it is a
complicated surgery.26,28 Thus, the conservative thing to do in
splenic trauma is splenectomy and it is prudent to err on the side of
splenectomy in all major multiple trauma and military cases.24,25
Superﬁcial splenic tears may be sutured using absorbable mattress
sutures buttressed with Surgicel, teﬂon or omentum. Ligation of
segmental vessels at the splenic hilum may be useful in obtaining
haemostasis from a splenic tear. Topical haemostatic agents e.g.
microﬁbrillar collagen (ﬁbrin glue) and absorbable envelopes have
also been used successfully to preserve the spleen.1,28 Splenosis and
auto transplantationmay have someminor immunological function
buthavenotbeen shown tobeeffective inpreventingoverwhelming
post splenectomy infection.27 It seems likely that the normal splenic
vasculature is crucial for maximum protection. Indeed there has
been some uncertainty of the level of splenic function achieved by
partial splenectomy especially if more than half the spleen is
removed or the splenic artery has to be tied as the patient probably
loses most immunological beneﬁt.3 It would be prudent to institute
similar prophylactic measures in these patients to prevent infection
as for asplenic individuals.293.1.1. Non-operative management
The current management of trauma is usually dictated by the age
of the patient, the experience of the institution, the individual sur-
geon and the type of trauma.1 Non-operative management of splenic
trauma has also become an option. 20e40% of laparotomies per-
formed for haemoperitoneum reveal that bleeding has stopped and
that the injuries do not require surgery.20 The practice began in the
1970’s in paediatric patients and was highly successful with an
average failure rate of 10.8%. The majority of failures occurring in the
ﬁrst 24 h.30 In an isolated splenic trauma in a haemodynamically
stable patient with no evidence of continuous bleeding, regular ob-
servations and haemoglobin measurements may be suitable for at
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delayed rupture after a period of several days (or even of 2e3weeks).
This equally dangerous condition may arise when the damage to the
spleen is less severe. The laceration may become temporarily sealed
eoff by omentum or by blood clot or the bleeding may at ﬁrst be
conﬁned within the capsule of the organ (subcapsular).22 A patient
under non-operative management for blunt abdominal injuries
should be admitted initially to ICU/HDU for at least 48e72 h for close
monitoring of vital signs, repeated clinical examinations and follow-
up investigations as indicated. But splenectomy or splenic repair is
warranted in an unstable patient despite resuscitation.31 Arteriog-
raphy with embolisation are increasingly important adjuncts to non-
operative management of splenic injuries.20,28
3.2. Relative indications for splenectomy
The relative indications for splenectomy includes hyper-
splenism, symptomatic splenomegaly and destruction of abnormal
blood cells in the spleen.1,9 Splenectomy is performed in patients
having haemolytic anaemia (e.g., hereditary spherocytosis [HS],
and autoimmune haemolytic anaemia) because the intrinsically
abnormal or antibody-coated red blood cells are prematurely
destroyed by splenic macrophages (Table 3). Because splenectomy
can ameliorate the underlying anaemia, it is often considered the
treatment of choice although none of these conditions can be cured
by splenectomy. Two facts must be established before splenectomy
in haematological patients. Firstly, the spleen must be shown to be
the site of excessive destruction of red cells, by examination of theTable 3
Relative indications and beneﬁts of splenectomy.11
Condition Degree of
splenomegalya
Indications for
splenectomyb
1. Blood and reticuloendothelial disease
a) Haemolytic
i. Congenital haemolytic anaemia D DDD
ii. Acquired haemolytic anaemia DD DD
iii. Thalassaemia D D
b) Haematological malignancy
i. Acute leukaemia D 0
ii. Chronic myeloid leukaemia DDD D
iii. Chronic lymphatic leukaemia DD D
iv. Lymphoma (Hodgkin’s) D D
c) Myeloproliferative disorders
i. Polycythaemia vera DD 0
ii. Myeloid metaplasia (myeloﬁbrosis) DDD D
d) Thrombocytopaenic disorders
i. Acute ITP þ D
ii. Chronic ITP DD DDD
2. Infective and inﬂammatory
a) Parasites (hydatid) DD DDD
b) Protozoal (malaria) DDD D
c) Inﬂammatory (Felty’s syndrome) DD D
3. Neoplastic
a) Angioma þþ 0
b) Cysts DD DDD
c) Metastases D 0
4. Cryptogenic
a) Tropical splenomegaly DDD D
b) Non-tropical splenomegaly DDD DDD
5. Congestive
a) Portal hypertension
i. Intrahepatic D D
ii. Extrahepatic DD D
6. Metabolic storage disorders
a) Amyloidosis þþ 0
b) Gaucher’s disease DDD D
a Degree of splenomegaly: þþþ ¼ marked (below umbilicus); þþ ¼ moderate
(4e8 cm below costal margin); þ ¼ slight (4 cm ejust palpable).
b Indications for splenectomy: þþþ ¼ beneﬁted by splenectomy; þþ ¼ often
beneﬁted by splenectomy; þ ¼ splenectomy sometimes indicated.bone marrow and of peripheral blood and isotope studies to illus-
trate excessive uptake in the spleen. Secondly, the bone marrow
must be shown capable of producing sufﬁcient new cells to correct
the cytopenia in the absence of the spleen. Otherwise, no reversal
of cytopenia is possible and the patient’s condition will continue to
deteriorate.1 Where splenectomy is being carried out for haema-
tological disorders a careful search should be also be made for
accessory spleens.9
The long-term thromboembolic risk which is higher in haema-
tological disorders associated with ongoing haemolysis, particu-
larly thalassaemia intermedia, has led to a more non-operative
approach.14 In comparison, patients with ITP appear to be at
lower risk of adverse effects of splenectomy, which maintains its
place as the potentially most curative and safe second-line treat-
ment. However, a splenectomy-sparing approach is also emerging
for ITP, and recent guidelines recommend that this procedure is
deferred until 12months following ITP diagnosis, to allow sufﬁcient
time for possible remission.32
3.2.1. Red cell disorders
Red cell disorders including hereditary spherocytosis, ellipto-
cytosis, pyruvate kinase deﬁciency present with severe anaemia,
haemolytic crisis, chronic leg ulcers and sometimes pigment gall-
stones in the former.9 Splenectomy reliably corrects the clinical
picture with very low mortality and morbidity, but is usually
delayed beyond ﬁve years of age to reduce the risk of overwhelming
post splenectomy infection.33 Cholecystectomy is done if there is
associated gallstone disease.1,9
3.2.2. Thalassaemia syndromes
Thalassaemia syndromes are inherited disorders in which the
rate of synthesis of one or more globin chain are reduced resulting
in defective erythropoiesis, haemolysis and consequent marked
splenomegaly and hypersplenism with increasing transfusion re-
quirements and severe iron overload. Splenectomy reduces the
need for blood transfusion requirements and it is usually done
before six and eight years.9,14 As the risk of thrombotic complica-
tions and sequelae (venous thrombosis and pulmonary hyperten-
sion) arising after an average interval of about 8 years is particularly
prominent in patients who underwent splenectomy, the current
thrust in prevention is to avoid splenectomy, even if this choice
entails a greater need of red cell transfusion and iron chelation. It
has also been shown that in splenectomized patients with thalas-
saemia intermedia who developed thrombosis, the platelet count
was much higher than in those who did not in spite of being
asplenic. Although it remains to be established whether or not the
high platelet count is the cause of thrombosis, it is reasonable to
recommend aspirin (100e300 mg daily) to patients at higher risk
because of a high platelet count.15
3.2.3. Homozygous sickle cell disease
Homozygous sickle cell disease is characterized by chronic
haemolysis and recurrent episodes of tissue infarction. Repeated
splenic infarction usually causes ‘autosplenectomy’ before adult-
hood, but splenectomy may occasionally be required for persistent
hypersplenism.8 Acute splenic sequestration is the second most
common cause of death in the ﬁrst decade of life and has a high rate
of recurrence.34 Splenectomy may thus be indicated for infants
with recurrent acute splenic sequestration characterized by rapidly
falling haemoglobin due to pooling of blood in an acutely enlarged
spleen.35 Patients who have a severe episode of acute splenic
sequestration and are below age 2 years should be placed in a
chronic transfusion programme to keep HbS level below 30% until a
splenectomy is performed at age 2 years.36 Splenectomy, if full, will
prevent further sequestration and if partial, may reduce the
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lack of evidence from trials showing that splenectomy improves
survival and decreases morbidity in people with sickle cell disease.
There is a need for a well-designed, adequately-powered, ran-
domized controlled trial to assess the beneﬁts and risks of sple-
nectomy compared to transfusion programmes, as a means of
improving survival and decreasing mortality from acute splenic
sequestration in people with sickle cell disease.35 Infection is still
the commonest cause of death irrespective of splenectomy.34e36
3.2.4. Platelet disorders
Splenectomies have been used to treat immune thrombocyto-
penic purpura (ITP) since 1913.9,37 However its long-term safety is
not well elucidated.32,38,39 In ITP the spleen plays a dual role,
serving as the main site of both antiplatelet antibody production
and destruction of antibody-coated platelets. Therefore removing
the spleen may reduce the amount of anti-platelet antibodies in
addition to removing the antibody-coated platelets. While a sple-
nectomy may raise the platelet count, it does not eliminate ITP
since the antibody-coated platelets remain in circulation.38
Although the spleen is often the major site of antibody-coated
platelet destruction, platelets may also be removed from circula-
tion by the liver, by a combination of the spleen and liver, or within
the blood stream. Therefore, splenectomies are not always suc-
cessful in raising the platelet count and may fail over time,
prompting a return of low platelets. The sequestration site is a good
predictive element in the short-term efﬁcacy of splenectomywith a
platelet count exceeding 100  109/l if splenic sequestration
occurred alone but much less with mixed and least with hepatic
sequestration.38,39 Splenectomy is indicated following failed
response to steroid treatment and about 70% achieve an immediate
and sustained platelet response after splenectomy but 7% achieve a
delayed response. All accessory spleens must be sought and
removed. If the platelet count is less than 70,000 pre-operatively
then fresh platelets are given once the splenic artery is clamped
otherwise they are “consumed” in a fewminutes by the unclamped
spleen. For those who do respond, 30e35% relapse over time.1,9,32
Previous response to corticosteroids or other treatments are not
very good predictors of splenectomy success. Age under 40 years is
the only positive predictive factor for the long term response to
splenectomy in ITP.40 Researchers suggest that a raised serum
biomarker protein haptoglobin (Hp) that binds to free haemoglobin
released by red blood cells predicts long-term response to sple-
nectomy for ITP in about 80% of cases.41 In a small proportion of the
splenectomized ITP population a second surgery is occasionally
required to remove an (extra)accessory spleen if the patient has
relapsed following a successful ﬁrst surgery. The ﬁrst meta-analysis
of randomized clinical trials and observational studies on rituximab
has shown its effectiveness as a splenectomy-avoiding option in
adult chronic ITP. Age was also the most relevant effect and ritux-
imab should be used earlier in non-splenectomised patients.42
Laparoscopic splenectomy (LS) is preferred when possible in ITP
as these patients are on steroids with risk of infection and poor
wound healing.43 A recent retrospective study demonstrated a 6.4%
conversion rate to open surgery which was mostly due to larger
spleens.44 A previous comparative study on operations on massive
splenomegaly had demonstrated a 6.6% conversion rate to open
and despite a signiﬁcant longer operating time, the post operative
recovery following laparoscopic splenectomy was smoother with
lower morbidity and shorter post operative hospital stay.45
3.2.5. Lymphoproliferative disease (Hodgkin’s/Non-Hodgkin’s
lymphoma)
Clinical studies have not demonstrated an improvement in
prognosis following splenectomy and the indications arediminishing with the effectiveness of CT scanning in staging Hodg-
kin’s disease and the responsiveness to chemotherapy.21 Splenec-
tomy, may on occasion be required to make a positive diagnosis
because of the suspicion of an underlying lymphoma, reticulosis or
inﬁltrative condition. Several investigations have suggested that
splenectomy in patients with Hodgkin’s disease increases the risk for
secondary leukaemia independent of treatment.19
3.2.6. Myeloﬁbrosis
Splenectomy formyeloﬁbrosis does not prolong survival butmay
be indicated as a palliativemeasure for symptomatic splenomegaly.1
The proliferative process affect the bone marrow, liver, spleen and
lymph nodes. The spleen may be grossly enlarged and portal hy-
pertension may develop. Early post operative morbidity and mor-
tality are very high due to impaired haemostasis, large spleen and
the usually elderly patients in poor general condition.46 Splenec-
tomy should be performed very occasionally for severe pain and
hypersplenism (low haemoglobin and lowwhite blood cell count) at
an earlier stage of the disease. Otherwise conservative treatment
with blood transfusion for anaemia may give better palliation.47
3.2.7. Malaria
Comparison of infected patients with or without spleens sup-
ports the idea that the spleen removes dead or damaged intracel-
lular parasites and returns intact erythrocytes into the blood
stream.7,48 Splenectomy is therefore not indicated for symptomatic
splenomegaly unless the spleen has ruptured.22
3.2.8. Congestive splenomegaly
Congestive splenomegaly from intrahepatic or extrahepatic
portal venous obstruction is most commonly caused by cirrhosis.
Splenectomy is reserved for the rare patient with severe residual
thrombocytopaenia after portasystemic shunting.49 If splenic
venous thrombosis is the underlying cause then splenectomy is the
treatment of choice.1,9
3.2.9. Felty’s syndrome
Felty’s syndrome is characterized by rheumatoid arthritis and
splenic neutropenia, commonly associated with anaemia and
chronic leg ulcers. Many immunological and rheumatological dis-
orders are associated with impairment of the spleen’s phagocytic
and immunological functions. Transient functional hyposplenism
may also occur during therapy with corticosteroids and after
pharmaceutical reticulo-endothelial blockadewith intravenous IgG
or anti-D immunoglobulin. Splenectomy controls the neutropenia
in the majority of patients with serious or recurrent infections or
non healing leg ulcers.50
4. Hazards of splenectomy
The complications of splenectomy may be conveniently divided
into acute, short and long term as shown in Table 4.
4.1. Haemorrhage
During operation bleeding can occur from divided adhesions, a
tear in the splenic capsule, fromthe splenicvessels or short gastrics or
from the tail of the pancreas. After operation, reactive haemorrhage
mayoccur from the small vessels in the posterior abdominalwall and
diaphragm.Thereforehaemostasismustbemeticulous toprevent the
developmentof a largehaematoma,whichmaybecome infected. The
operative mortality varies between 3 and 15%, depending upon the
physical stateof thepatient andthe condition forwhich theoperation
was performed.1 The mortality is particularly high (30%) following
splenectomy for myeloproliferative disorders (i.e. myeloﬁbrosis,
Table 4
Complications of splenectomy.
Acute Short term Long term
Haemorrhage
 During
 Immediately after
Overwhelming postoperative
infection (OPSI) þ/
disseminated
intravascular coagulation
(DIC)
OPSI þ/ DIC
Pulmonary atelectasis
and pneumonia
Pulmonary infection Pulmonary
infection
Sympathetic pleural
effusion
Subphrenic
abscess/cellulitis
Deep vein thrombosis Venous
thrombosis
Gastric ileus Spleno-portal thrombosis
(fever, abdominal
complaints)
Pulmonary
hypertension
Acute pancreatitis Enhanced
atherosclerosis
Thrombocytosis
and leucocytosis
(peaks 7the14th day)
Arterial
thrombosis
Severe thrombosis
after splenectomy for
myeloproliferative disorders
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are as a result of bleeding. The platelets in myeloproliferative disor-
ders are a part of the malignant population and defects in function
have been reported. Therefore the assessment of platelet function or
bleeding time should be performed before splenectomy in this group
and the possibility of platelet transfusion despite a normal platelet
count should be considered.46,47 Patients over 65 have a higher
complication and fatality rate.464.2. Thromboembolic
Thromboembolic complications following splenectomy for
haematological diseases occur in up to 10% of patients and may
range from portal vein thrombosis to pulmonary embolism and
deep vein thrombosis.51 Given the increased platelet count post-
splenectomy which is maximal by the 10th day, deep vein throm-
bosis (DVT) or pulmonary embolism has also to be considered as a
cause of post operative pyrexia. Both DVT and small pulmonary
embolism may otherwise be silent although they may of course be
the harbinger of a massive pulmonary embolism.52 Splenic/portal
vein thrombosis is an alarming complication of splenectomy pre-
senting with fever and abdominal pain and a mortality ofw10%.51e
54 The median time from splenectomy to symptomatic splenic vein
thrombosis is 8e12 days.52 Fatal outcomes have been reported 7e
35 days after splenectomy for autoimmune haemolytic anaemia,
immune thrombocytopaenia and indolent lymphoma respec-
tively.53 Retrospective studies have shown the incidence of symp-
tomatic splenic/portal vein thrombosis varying from 0.7% to 8%.53,54
The overall risk addressed in prospective and retrospective ran-
domized or non-randomized trials is 3.3%. Risk factors are big
spleens (i.e. myeloproloferative disorders and hereditary haemo-
lytic anaemia) whereas risk is low in autoimmune thrombocyto-
paenia and trauma. The incidence is approximately the same in
laparoscopic and open splenectomy.54 A high index of suspicion,
early diagnosis by contrast eenhanced computed tomography and
prompt anticoagulation are key to successful outcome.54 Generally
prior to splenectomy, correction of preoperative coagulation ab-
normalities, intensive post operative chest physiotherapy and an-
tiplatelet therapy with low dose aspirin if platelet counts rise
postoperatively above 800  109/l all make surgery safer.1 There
exist no standard recommendations for the duration and intensityof prophylactic anticoagulation which usually follow local institu-
tional protocols. Post operative antithrombotic prophylaxis ranged
from no prophylaxis to heparin for seven days or longer.53 Treat-
ment of symptomatic splenic vein thrombosis with heparin and
warfarin leads to complete resolution of thrombosis in 67%, to
partial resolution in 13%, but persistent occlusion, portal hyper-
tension or cavernoma occurred in 20%.54 The long-term outcome of
treatment failures is unknown. Well-designed randomized studies
on the prophylaxis of venous thromboembolism after splenectomy
are urgently needed.
4.3. Subphrenic abscess
Subphrenic abscess is not common. It may arise from an infected
haematoma or infection following injury of the adjacent stomach
or colon. Patients with autoimmune disorders e.g. immune
thrombocytopenic purpura (ITP) who have been on steroids have a
high frequency of subphrenic abscesses and aremostly aborted by a
course of antibiotics.47
4.4. Chest infection
The patients with lymphoproliferative malignancies e.g. Hodg-
kin’s lymphoma, chronic lymphocytic leukaemia have a high
morbidity from infective complications especially bronchitis and
pneumonia.6,21,47 By being minimally invasive with less pain, the
laparoscopic technique as opposed to openmay decrease the risk of
post operative chest infections due to atelectasis and sputum
retention.45
4.5. OPSI
The major long-term risk of splenectomy is overwhelming post-
splenectomy infection (OPSI).2 Post trauma, the life-time risk of
OPSI is 0.1e0.5% and has a mortality of up to 50%.12 The risk of
infection is life long as cases of fulminant infection have been re-
ported more than 20 years post splenectomy and is greater with
encapsulated organisms -streptococcus pneumonia, nessieria
meningitides, and H inﬂuenza.29,55 Pneumococcal infection is most
common and carries a mortality rate of up to 60%.2,12 Infectionwith
H inﬂuenza type B, whilst much less common is nonetheless sig-
niﬁcant, particularly in children. The risk of OPSI is greatest during
the ﬁrst 3- years post splenectomy; greater in children especially
under 5 years and who have had splenectomy for trauma (>10%
excess risk) than adults (<1%).2,29,56 The risk of infection with
encapsulated organisms is increased in immunosuppressed or
immunodeﬁcient individuals (e.g. HIV, myeloma, leukaemia).29,57
5. Prevention of overwhelming post splenectomy infection
(OPSI)
Overwhelming infection in hyposplenic or asplenic patients
thus remains an area of concern.2,12 This may include infection by
unusual serotypes not included in the vaccinations.62,63 All sple-
nectomized patients greater than 2 yrs old and those with func-
tional hyposplenism should receive pneumococcal vaccination,
haemophilus inﬂuenzae type b conjugate vaccine and meningo-
coccal conjugate vaccine at least 2 weeks before splenectomy in
order to ensure an optimal antibody response. Immunisation
should be administered following emergency splenectomy, but the
effect is not as good, although still better than not being given.29
Time frames may be different for those with immunosuppressive,
sickle-cell disorders and on immune suppressing therapies.29
Because of waning immunity timing of revaccination may be
determined by levels of protective antibody (Table 5).29,58,64
Table 5
Summary of British haematology guidelines on timing and type of vaccinations in elective and emergency splenectomy.29
Class OPSI prophylaxis Timing
 <2yrs  None (immature immune system)
 >2yrs  Immunization  At least 2 weeks before splenectomy for
optimal antibody response Functional hyposplenism
(e.g. sickle cell, ITP, coeliac dis)
 Emergency splenectomy  Immunization Following emergency splenectomy
 Immunization effect not as good
 Still better than not being given
 Asplenic patients  Immunization
 Add inﬂuenza vaccine (prophylaxis against
secondary bacterial infection)9
 Splenectomy in underlying immunosuppressive
disease (e.g. lymphoproliferative) or
sickle-cell disorder37
 Immunization
 Life-long prophylactic antibiotics
 Monitor response to pneumococcal vaccination
 Timing of revaccination determine by levels of
protective antibody
 Splenectomy in patients on immune
suppressing therapies (chemotherapy
and/or radiotherapy)
Immunization
 Life-long prophylactic antibiotics
 Immunization delayed at least 6 months following
chemo/radiotherapy
 High risk patients (<18 yrs, immunosuppressed)  Life-long oral prophylactic antibiotics against
pneumococcal infection (penicillins/macrolides)
 Prompt systemic antibiotic treatment for infection
Regularly reviewed in light of local pneumococcal
resistance patterns
 Low risk patients  Counselled on risks and beneﬁts of life-long
antibiotics and may choose to discontinue
 Carry a supply of appropriate antibiotics for emergency
 Malaria belt  Antimalarial prophylaxis
 Treat malaria infection early and aggressively
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Regardless of indication, the adjusted short- and long-term risk
of death for splenectomised patients was higher than the general
population. Within 90 days post-splenectomy, the adjusted relative
risk (RR) for deathwas 33.6%.59 This risk declined substantially after
90 days post-splenectomy but remained higher 365 days post-
splenectomy for all indications compared to the general popula-
tion.59 This may suggest that the indication for splenectomy is the
determinant factor on outcome. The best prognosis being with
splenectomy for trauma than for an associated disease process.60
This is also in line with the observation that the ability of an
asplenic individual to mount an adequate protective antibody
response may relate more to the indication for, or age at, splenec-
tomy, and to the presence of underlying immune suppression than
the absence of the spleen.61
With the largely signiﬁcant success of prophylactic measures to
prevent OPSI, other complications of asplenia are surfacing.14e18,65
The compelling evidence for a hypercoagulable state after splenec-
tomy performed for various indications is probably compounded by
other underlying conditions, especially intravascular haemolysis as
seen in thalassaemia and sickle cell disease14 Recent observations
suggest thataspleniamaybea risk factor forpulmonaryhypertension
irrespective of the underlying condition.15 Although there is sub-
stantial evidence that pulmonary hypertension and venous throm-
bosis occur at increased rates in asplenic hosts, the strength of
evidence is less convincingwithatherothrombosis causingdementia,
myocardial infarction and stroke. However, the observed memory
disturbances due to ischaemic small vessel disease associated with
platelet disorders following splenectomy warrants further investi-
gation.66 Thus, vascular events after splenectomy are likely to be
multifactorial. It may result from some combination of hypercoagu-
lability, platelet activation, disturbance and activation of the endo-
thelium, and altered lipid proﬁles.67 Absence of this extremely
sensitive ﬁlter function of the spleen may permit particulate matter
and damaged cells to persist in the blood stream, thereby perturbing
and activating the vascular endothelium leading to a shift in vascular
homeostasis toward enhanced coagulation. Unfortunately, despite
these risks alongside the potential beneﬁts no condition is actuallycured by splenectomy. The spleen is however simply an enlarged
lymph node.
7. Conclusions
The spleen, whether anatomically and physiologically normal or
diseased, may signiﬁcantly worsen the clinical picture in a variety of
medical disorders. However, splenectomy shouldbeundertaken only
after careful balancing of the short and long term risks and potential
beneﬁts to the patient. Most of this risk seems to be due to the un-
derlying splenectomy indication and not to splenectomy alone.
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